Objective: To analyze the effects of SCN1A and SCN2A gene polymorphism on efficacy of sodium valproate in children with epilepsy. Methods: SCN1A (rs10188577

rs2298771

rs3812718

rs1813502) and SCN2A (rs2304016

rs17183814) polymorphisms of 128 children with epilepsy (76 cases in the effective group and 52 cases in the ineffective group) were detected by PCR and Sanger sequencing. Correlation between genotype

allele frequency and efficacy of sodium valproate was analyzed by unconditional Logistic regression

and the difference of blood drug concentration of sodium valproate in patients with different genotypes was analyzed. Results: SCN1A gene rs3812718 polymorphism was related to the therapeutic effects of sodium valproate. Patients with GA and AA genotypes were effectively treated with sodium valproate (GG vs GA: OR=1.186

95%CI: from 0.965 to 2.304

P=0.015; GG vs AA: OR=1.252

95%CI: from 1.007 to 3.254

P=0.002). The frequency of A allele at rs3812718 of SCN1A gene in the effective group was significantly higher than that in the ineffective group (OR=1.452

95%CI: from 1.052 to 2.695

P=0.010). There was no statistically significant difference between the other gene loci groups (P>0.05). Conclusion: The rs3812718 polymorphism of SCN1A gene may be related to the antiepileptic effect of sodium valproate.